Sleep onset

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

Retrieved on: 
Monday, July 6, 2020
Branches of biology, Chemical compounds, Biology, Molecular neuroscience, Hypnotics, Cyclopropanes, Lemborexant, Organofluorides, Pyrimidines, Eisai, Insomnia, Sleep onset

2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.

Key Points: 
  • 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.
  • DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
  • (9)
    Through the launch of DAYVIGO, Eisai will continue to prioritize the provision of appropriate usage and safety information.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .